CAI
CARIS LIFE SCIENCES, INC.Marquee-fund ownership over time
This quarter's activity
New positions opened
Positions exited
None.
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Citadel Advisors re-entered | Q3 2025(8Q snapshot) | 3Q | $37 | $15 | -59% |
| Coatue Management | Q3 2025 | 3Q | $37 | $15 | -59% |
| D.E. Shaw re-entered | Q3 2025(8Q snapshot) | 3Q | $37 | $15 | -59% |
| Millennium Management | Q3 2025(8Q snapshot) | 3Q | $37 | $15 | -59% |
| Point72 Asset Management | Q3 2025(8Q snapshot) | 3Q | $37 | $15 | -59% |
| Renaissance Technologies | Q4 2025(8Q snapshot) | 2Q | $24 | $15 | -38% |
| AQR Capital Management | Q2 2026(8Q snapshot) | 1Q | $15 | $15 | +4% |
| Duquesne Family Office | Q2 2026 | 1Q | $15 | $15 | +4% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Soros Fund Management | Q3 2025 | Q1 2026 | → $21 | -44% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Caris Life Sciences, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jun 2, 2026 — the most recent Form 4 on file — not from today.
- Form 40001180770-26-000003Jun 2, 2026
- Form 40001662103-26-000002Jun 2, 2026
- Form 40002071923-26-000005May 18, 2026
- Form 40002072013-26-000004May 18, 2026
- Form 40002071953-26-000004May 18, 2026
- Form 40002071959-26-000006May 18, 2026
- Form 40001034380-26-000004May 18, 2026
- Form 40001724161-26-000005May 12, 2026
- Form 40002072013-26-000002Mar 10, 2026
- Form 40002071923-26-000002Mar 10, 2026
- Form 40002071953-26-000002Mar 10, 2026
- Form 40002071959-26-000004Mar 10, 2026
- Form 40001034380-26-000002Mar 10, 2026
- Form 40002038687-26-000004Mar 2, 2026
- Form 40001724161-26-000002Feb 27, 2026
Fundamentals
XBRL · CARIS LIFE SCIENCES, INC.Annual figures sourced directly from CARIS LIFE SCIENCES, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Caris Life Sciences, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventJun 5, 2026
- 10-QQuarterly reportMay 8, 2026
- 8-KMaterial eventMay 7, 2026
- DEF 14AProxy statementApr 23, 2026
- 8-KMaterial eventApr 2, 2026
- 10-KAnnual reportMar 3, 2026
- 8-KMaterial eventFeb 26, 2026
- 8-KMaterial eventJan 12, 2026
- 10-QQuarterly reportNov 5, 2025
- 8-KMaterial eventNov 5, 2025
- 8-KMaterial eventOct 30, 2025
- 10-QQuarterly reportAug 12, 2025
- 8-KMaterial eventAug 12, 2025
- 8-KFORM 8-KJun 20, 2025
- S-1/ARegistration (IPO, amended)Jun 16, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| D.E. Shaw | Q2 2026 | open | $15 | $15 | +4% |
| AQR Capital Management | Q2 2026 | open | $15 | $15 | +4% |
| Duquesne Family Office | Q2 2026 | open | $15 | $15 | +4% |
| Citadel Advisors | Q1 2026 | open | $21 | $15 | -27% |
| Renaissance Technologies | Q4 2025 | open | $24 | $15 | -38% |
| Citadel Advisors | Q3 2025 | Q4 2025 | $37 | $24 | -36% |
| Soros Fund Management | Q3 2025 | Q1 2026 | $37 | $21 | -44% |
| Coatue Management | Q3 2025 | open | $37 | $16 | -56% |
| D.E. Shaw | Q3 2025 | Q1 2026 | $37 | $21 | -44% |
| Millennium Management | Q3 2025 | open | $37 | $15 | -59% |
| Point72 Asset Management | Q3 2025 | open | $37 | $15 | -59% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.